Clinical Trial Update: A Study of ICP-022 in Patients With R/R DLBCL [Phase 2]

View source ↗

Summary

Phase 2 study of ICP-022 in relapsed/refractory diffuse large B cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• ICP-022

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Diffuse Large B Cell Lymphoma | Phase 2 | Status: COMPLETED